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352Objective:We sought to identify predictors of structural valve deterioration after pulmonary valve replacement
in patients with tetralogy of Fallot.
Methods: A retrospective review of 227 patients with tetralogy of Fallot who underwent stented bioprosthetic
pulmonary valve replacement at Children’s Hospital Boston between 1994 and 2009 was performed. Patient and
valve characteristics were assessed as potential predictors of structural valve deterioration by using univariate
and multivariable analysis. Freedom from pulmonary valve reintervention and structural valve deterioration
were determined by using Kaplan Meier analysis.
Results: Two hundred twenty-nine pulmonary valve replacement operations were performed, with no early mor-
talities. Freedom from reintervention and structural valve deterioration were 94% (95% confidence interval,
87% 100%) and 74% (95% confidence interval, 63% 85%) at 5 years, respectively, and median time to rein-
terventionwas 6.4 years (range, 2 10.1 years). Younger age and higher indexed valve internal diameter were pre-
dictors of reduced time to structural valve deterioration. Among patients aged less than 20 years at the time of
pulmonary valve replacement, indexed valve internal diameter was a significant predictor of increased risk of
structural valve deterioration. Valvemanufacturer was not a significant predictor of structural valve deterioration.
Conclusions:Younger age at the time of pulmonary valve replacement and valve oversizing in patients less than
20 years of age at the time of pulmonary valve replacement were significant predictors of structural valve de-
terioration and could potentially affect the timing of pulmonary valve replacement and the extent of valve over-
sizing in small children. No statistically significant difference in valve performance was seen between
bioprosthetic valve types at short-term follow-up. (J Thorac Cardiovasc Surg 2012;143:352-60)Earn CME credits at
http://cme.ctsnetjournals.orgComplete surgical repair of tetralogy of Fallot (TOF) has
been successfully performed since the 1950s. Although fa-
vorable long-term outcomes have been documented, an in-
creasing number of patients are requiring reoperation after
initial TOF repair for pulmonary regurgitation (PR).1,2
Although the majority of patients with significant PR aree Department of Cardiovascular Surgery, Children’s Hospital Boston, Boston,
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The Journal of Thoracic and Cardiovascular Surgasymptomatic for many years, they remain at risk for
progressive right ventricular (RV) dilatation and reduced
ventricular function, development of arrhythmias, or
sudden death.3 Current indications for pulmonary valve re-
placement (PVR) include a right ventricular end-diastolic
volume index (RVEDVI) of 150 mL/m2 or greater, an RV
ejection fraction of 45% or less, right ventricular outflow
tract (RVOT) aneurysm, and significant clinical symptoms.4
PVR in these patients has previously been demonstrated to
provide significant improvement in RV function and exer-
cise tolerance.5,6
Although PVR with a bioprosthetic valve has become
standard practice in patients with TOF who demonstrate
indications for surgical intervention, durability and risk
factors for structural valve deterioration (SVD) and reinter-
vention in the RVOT position have not been defined. Infor-
mation regarding the durability of existing prostheses will
affect recommendations regarding the timing of PVR.4,7
Long-term data are available for bioprosthetic valve durabil-
ity in the aortic position,8-10 and these data are typically
extrapolated to decision making and counseling for PVR.
Therefore this study sought to identify predictors for SVD
after stented bioprosthetic PVR in patients with TOF who
had undergone previous complete TOF repair.ery c February 2012
Abbreviations and Acronyms
CE ¼ Carpentier Edwards
ID ¼ internal diameter
MRI ¼ magnetic resonance imaging
PR ¼ pulmonary regurgitation
PS ¼ pulmonary stenosis
PVR ¼ pulmonary valve replacement
RV ¼ right ventricular
RVEDV ¼ right ventricular end-diastolic volume
RVEDVI¼ right ventricular end-diastolic volume
index
RVEF ¼ right ventricular ejection fraction
RVOT ¼ right ventricular outflow tract
SVD ¼ structural valve deterioration
TOF ¼ tetralogy of Fallot
TR ¼ tricuspid regurgitation
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DMATERIALS AND METHODS
Patient Population
Institutional review board approval was obtained before all data collec
tion. All patients with TOF (n 227) who underwent stented bioprosthetic
PVR between January 1, 1994, and December 31, 2009, at Children’s Hos
pital Bostonwere included in the study. Exclusion criteria included patients
who received a pulmonary homograft or mechanical valve as their method
of RVOT reconstruction. At our institution, placement of a stented biopros
thetic valve, when possible, is preferred over placement of stentless valves
or pulmonary homografts because of concerns about durability. The type of
stented bioprosthetic valve implanted was based on the surgeon’s prefer
ence, and the size of the valve implanted was limited by the ability to aug
ment the RVOT. All patients were maintained on 81 mg of aspirin
postoperatively after bioprosthetic PVR. Follow up was obtained through
patients’ medical records and direct telephone contact.Intraoperative Management of the Tricuspid Valve
Repair of the tricuspid valve at the time of PVR was performed if there
was greater than moderate regurgitation or a structural malformation that
was unlikely to improve with PVR, such as leaflet perforation, flail leaflet,
or distortion secondary to a transvenous pacemaker wire. In the case of
structural malformations, a repair was performed for less than moderate tri
cuspid regurgitation (TR). The type of repair depended on the mechanism
responsible for poor valve function; in most patients closure of the antero
septal commissure was performed.Data Collection
Demographic, clinical, operative, and imaging data were obtained from
patients’ medical records. The type of valve implanted and other specifics
of the surgical procedures performed were obtained from operative reports.
Review of preoperative and postoperative echocardiographic and magnetic
resonance imaging (MRI) reports was performed, and relevant measure
ments were recorded. Echocardiographic measurements included qualita
tive degree of PR, pulmonary stenosis (PS), TR, peak pulmonary valve
gradient (in millimeters of mercury), and estimated RV pressures (in mil
limeters of mercury) by TR jet. Data recorded from MRI reports included
right ventricular ejection fraction (RVEF), pulmonary and tricuspid regur
gitant fractions, right ventricular end diastolic volume (RVEDV), and
RVEDVI. Preoperative imaging data were collected from studies closestThe Journal of Thoracic and Cain proximity to the date of the operation, and postoperative imaging data
were collected from the most recent studies.Structural Valve Deterioration
The development of SVDwas defined as the need for repeat PVR or pul
monary valve intervention at catheterization or development of PR or PS
graded at greater than or equal to moderate on follow up echocardiographic
analysis or MRI, as defined by recent guidelines.11 Follow up for SVD in
cluded patients undergoing first time and repeat PVR.
Statistical Analysis
Data are described as numbers with frequencies and percentages, me
dians with interquartile ranges, and means with standard deviations. Actu
arial freedom from pulmonary valve reintervention and SVD were
determined by using the Kaplan Meier method, with age groups compared
by using the log rank test and the Greenwood formula used for constructing
95% confidence intervals (CIs) around the curves.12 Paired t tests were
used to assess improvements in postoperative imaging data, and the
Wilcoxon signed rank test was applied to compare preoperative and
follow up grades of PR, PS, and TR. Two tailed P values of less than .05
were considered statistically significant. To control for possible confound
ing variables, the multivariable Cox proportional hazards regression model
was applied to identify significant risk factors for SVD and included all var
iables with statistical significance on univariate analysis.13 In patients less
than 20 years old at the time of PVR, we applied logistic regression mod
eling to estimate the probability of SVD with a 95% CI based on indexed
valve internal diameter (ID). Statistical analysis was performed with the
SPSS software package (version 19.0; SPSS, Inc, Chicago, Ill).RESULTS
Patients’ Characteristics
A total of 227 patients with TOF undergoing 229 PVR
operations were included in the study. Preoperative imaging
and complete follow-up with postoperative imaging after
discharge were available in 176 (77%) of 229 patients. De-
mographic and baseline clinical data of the study population
are summarized in Table 1. All patients had previously un-
dergone TOF repair. The congenital heart disease diagnosis
of TOF with pulmonary atresia was noted in 46 (20%) pa-
tients, and TOF with absent pulmonary valve was noted in
13 (6%) patients. The median duration of postoperative
follow-up was 2.3 years (range, 0.1 14.6 years), and
mean duration was 3.2 2.8 years. Both MRI and echocar-
diographic data were available in 57 (25%) patients preop-
eratively and postoperatively. For the remainder of patients
with available imaging data, echocardiography was the im-
aging modality used for data analysis.Pulmonary Valve Replacement
Operative PVR data are summarized in Table 2. Four
types of stented bioprosthetic valves were implanted: the
Carpentier Edwards (CE; Model 2700; Edwards Lifescien-
ces, Irvine, Calif) Perimount valve, the CE Magna valve
(Model 3000 TFX), the Sorin (Sorin Group, Milan, Italy)
Mitroflow valve, and the CE porcine valve (Model 2625).
Duration of follow-up after PVR differed depending on
the valve type implanted: CE Perimount, 5.5 years (0.5 10rdiovascular Surgery c Volume 143, Number 2 353
TABLE 1. Patients’ characteristics at the time of PVR
Characteristic All patients (n 227)
Sex
Male 142 (63%)
Female 85 (37%)
Median age at TOF repair (y) 0.8 (0.01 37.0)
Median age at PVR (y) 19.4 (0.4 58.1)
Median time to PVR (y) 17.5 (0.37 46.13)
NYHA class
I 111 (49%)
II 95 (41%)
III 20 (9%)
IV 1 (1%)
Preoperative RVEF (%) 47  9
Preoperative RVEDV (mL) 290  116
Preoperative RVEDVI (mL/m2) 186  53
PR fraction 0.46  0.13
NYHA, New York Heart Association; PR, pulmonary regurgitation; PVR, pulmonary
valve replacement; RVEDV, right ventricular end-diastolic volume; RVEDVI, right
ventricular end-diastolic volume index; RVEF, right ventricular ejection fraction;
TOF, tetralogy of Fallot.
TABLE 3. Effect of PVR on clinical characteristics
Characteristic Preoperative Postoperative P value
MRI (n 57)
RV ejection fraction 47  9 44  10 .002
RVEDV (mL) 290  116 244  113 <.001
RVEDVI (mL/m2) 186  53 141  51 <.001
PR fraction 0.46  0.13 0.13  0.11 <.001
Echocardiography
Degree of PR
None 2 (1%) 90 (51%) <.001
Mild 6 (3%) 56 (31%)
Moderate severe 217 (96%) 32 (18%)
Degree of PS
None 143 (64%) 116 (65%) .164
Mild 45 (20%) 52 (29%)
Moderate severe 36 (16%) 10 (6%)
Degree of TR
None 61 (27%) 78 (44%) <.001
Mild 128 (56%) 87 (49%)
Moderate severe 38 (17%) 12 (7%)
Peak PV gradient (mm Hg) 38  23 26  17 .008
Estimated RV pressure
(mm Hg)
42  20 36  15 .011
Paired t tests were used to assess improvements in the most recent postoperative im-
aging data, and the Wilcoxon signed-rank test was applied to compare preoperative
and follow-up grades of pulmonary regurgitation, pulmonary stenosis, and tricuspid
regurgitation. MRI, Magnetic resonance imaging; PR, pulmonary regurgitation; PS,
pulmonary stenosis; PV, pulmonary valve; PVR, Pulmonary valve replacement; RV,
right ventricular; RVEDV, right ventricular end-diastolic volume; RVEDVI, right ven-
tricular end-diastolic volume index; TR, tricuspid regurgitation.
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Dyears); CEMagna, 2.4 years (0.3 6 years); Sorin Mitroflow,
1 year (0.1 2.7 years); CE porcine valve, 8.7 years (6.0 14.6
years). The majority of patients underwent a concomitant
procedure at the time of PVR (74%). PVR was performed
either within a tube graft conduit or directly into the native
RVOT, with or without an anterior patch. All patients sur-
vived to discharge, with a median hospital length of stay
of 5 days (interquartile range [IQR], 4 7 days).
The effect of PVR on clinical parameters is summarized
in Table 3. Significant improvements were seen in RVEDV,
RVEDVI, RV pressure, PV gradient, and PR fraction at the
time of the most recent postoperative follow-up imaging. ATABLE 2. PVR characteristics
Characteristic All PVRs (n 229)
Presence of RV aneurysm 44 (20%)
Valve type
CE Perimount 61 (27%)
CE Magna 97 (42%)
Sorin Mitroflow 58 (25%)
Porcine 13 (6%)
Method of implantation
Native RVOT 211 (92%)
Valve in conduit 18 (8%)
Median bioprosthesis size
(mm)
27 (range, 19 31)
Additional procedures
Aneurysm resection 10 (4%)
Pulmonary arterioplasty 43 (19%)
TV intervention 29 (13%)
Closure of residual shunts 69 (30%)
RA maze procedure 10 (4%)
Continuous data are expressed as means  standard deviations, and categorical data
are expressed as numbers (percentages). CE, Carpentier–Edwards; PVR, pulmonary
valve replacement; RA, right atrial; RV, right ventricular; RVOT, right ventricular out-
flow tract; TV, tricuspid valve.
354 The Journal of Thoracic and Cardiovascular Surgstatistically significant decrease in RVEF was seen at the
most recent postoperative MRI. There were 7 postdischarge
deaths in the study population, with a median time to mor-
tality of 3.5 years (range, 1 11 years). Causes of death for
these patients were not able to be determined, but in 5 pa-
tients there was a study showing no SVD before the time
of death. Three of these studies occurred greater than 1
year before the time of death.
Tricuspid Valve Regurgitation
In our cohort a total of 29 (13%) of 229 patients under-
went a concomitant tricuspid valve intervention at the
time of PVR. Of these, 26 underwent tricuspid valve repair,
and 3 underwent tricuspid valve replacement. There was
a significant difference in the number of patients with
moderate-to-severe TR preoperatively compared with post-
operatively (17% vs 7%, P<.001), as seen in Table 3. In
patients who underwent PVRwithout concomitant tricuspid
valve repair, a decrease in TR gradewas observed in 32% of
the patients. However, 15% experienced an increase in TR
grade despite repair. Preoperative TR grade was not predic-
tive of improvement in TR grade postoperatively.
Event-Free Survival
In defining our population for Kaplan Meier analysis, 7
patient deaths were excluded because the cause of deathery c February 2012
TABLE 4. Risk factors for structural valve deterioration
Variable
Univariate
analysis
Multivariable Cox
proportional hazards
regression model
P value
Hazard ratio
(95% CI)
P
value
Younger age at PVR (y) <.0001* 0.95 (0.92 0.98) .04y
Sex .99 .43
Smaller size of implant (mm) <.001* .35
Higher indexed valve ID
(mm/m2)
<.001* 1.05 (1.02 1.09) .03y
Method of implantation
Valve in conduit .05* .31
RV ejection fraction (%) .07 .44
Increased RVEDV (mL) .02* .73
RVEDVI (mL/m2) .60 .77
PR fraction .80 .98
Peak PV gradient (mm Hg) .28 .86
Estimated RV pressure (mm
Hg)
.81 .90
Degree of PR .11 .83
Degree of PS .22 .69
Degree of TR .73 .67
Valve type
CE Perimount (reference)
CE Magna .003* .77
Sorin Mitroflow <.001* .68
Porcine .18 .84
CE, Carpentier–Edwards; CI, confidence interval; ID, internal diameter; PR, pulmo-
nary regurgitation; PS, pulmonary stenosis; PV, pulmonary valve; PVR, pulmonary
valve replacement; RV, right ventricular; RVEDV, right ventricular end-diastolic
volume; RVEDVI, right ventricular end-diastolic volume index; TR, tricuspid regur-
gitation. *Significant univariate association. ySignificant independent risk factor for
structural valve deterioration.
FIGURE 1. Freedom from reintervention and structural valve deteriora
tion (SVD). PVR, Pulmonary valve replacement.
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Dwas unknown and not clearly valve related. Of these 7
deaths, 2 patients did not have any postoperative imaging
follow-up, whereas the other 5 had postoperative imaging
with no evidence of SVD. SVD (repeat intervention, mod-
erate or severe PR on imaging, or both) was identified in
33 (14%) patients and was observed at a median time after
PVR of 4.3 years (range, 0.25 14 years). Freedom from
SVD at 2, 5, and 7 years was 96% (95% CI, 93% 99%),
74% (95% CI, 64% 84%), and 54% (95% CI,
40% 68%), respectively (Figure 1). Among the SVD
group, 15 of 33 patients (45% in the SVD group and 7%
in the study population) underwent a repeat pulmonary valve
intervention. Repeat surgical PVRwas performed in 5 (2%)
patients, transcatheter stented bovine jugular vein valves
were inserted in 7 (3%) patients, and percutaneous pulmo-
nary valve balloon dilation was performed in 3 (1%) pa-
tients. Median time to reintervention was 6.7 years (range,
2 14 years). Freedom from repeat pulmonary valve inter-
vention at 2, 5, and 7 years was 98% (95% CI, 95%
100%), 94% (95% CI, 88% 100%), and 74% (95% CI,
58% 90%), respectively.Predictors of SVD
Characteristics of both patients and valves were assessed
as potential predictors of SVD and are summarized in
Table 4. All variables that achieved statistical significance
by means of univariate analysis were included as candidates
within the multivariable Cox proportional hazards regres-
sion model. Younger age at the time of PVR (hazard ratio
[HR], 0.95; 95% CI, 0.92 0.98; P ¼ .04) and a higher in-
dexed valve diameter (HR, 1.05; 95% CI, 1.02 1.09;
P ¼ .03) were predictors of earlier time to SVD; however,
the 2-way interaction was also significant (P¼ .01), reveal-
ing that indexed valve ID was predictive of outcome only in
younger patients at the time of PVR. Indexed valve ID was
found to be inversely correlated with age (SpearmanThe Journal of Thoracic and Cacorrelation, 0.60; P< .0001). When stratifying by age
group, freedom from SVD in the younger patient group
(<20 years of age at the time of PVR) was 61% (95%
CI, 43% 79%) compared with 85% (95% CI, 73%
97%) in the older patient group (20 years of age at the
time of PVR; median, 30.6 years; range, 20.1 58.1 years)
at 5 years (Figure 2). The Cox regression model applied
to patients less than 20 years of age at the time of PVR in-
dicated a highly significant HR based on higher indexed
valve ID (HR, 1.08; 95% CI, 1.04 1.11; P<.001), whereas
the effect of indexed valve ID among patients 20 years of
age or older at the time of PVR was not significant in the
Cox regression analysis (P ¼ .93). In addition, 14 (93%)
of 15 patients who underwent a pulmonary valve reinter-
vention were less than 20 years old at the time of PVR.
There was no effect of sex, preoperative RVEF, RVEDV,
RVEDVI, estimated RV pressure, or peak PV gradient on
reduced time to SVD. The median size of the valves im-
planted at age less than 20 years at the time of PVR was
25 mm, whereas the size of the valves implanted at the
age of 20 years or greater at the time of PVR was 27 mm.
A moderate correlation was also found between age at therdiovascular Surgery c Volume 143, Number 2 355
FIGURE 3. Logistic regression curve predicting the probability of struc
tural valve deterioration (SVD) according to indexed valve internal diame
ter in younger patients.
FIGURE 2. Effect of age on freedom from structural valve deterioration.
PV, Pulmonary valve; PVR, pulmonary valve replacement.
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Dtime of PVR and the size of the implant (Pearson correla-
tion, 0.51; P < .001). Smaller implant size, increased
RVEDV, and use of conduit did not reach significance
when using Cox proportional hazards regression modeling.
Valve type implanted was not found to be a predictor of
SVD at short-term follow-up. The degree of preoperative
PR, PS, and TR did not have a significant effect on the de-
velopment of SVD.
Valve Oversizing
The range of indexed valve IDs within our patient popu-
lation was 8.7 to 60.1 mm/m2. The correlation identified be-
tween age at the time of PVR and indexed valve ID resulted
from the increased risk of SVD with increasing indexed
valve ID among patients less than 20 years of age at the
time of PVR, with no significant relationship seen in pa-
tients older than 20 years at the time of PVR. In the younger
age group a significant difference in indexed valve ID was
seen between the SVD (22.4 mm/m2) and non-SVD (16.3
mm/m2) groups (P<.004). There was no significant differ-
ence in indexed valve ID seen between the SVD (13.8
mm/m2) and non-SVD (14.2 mm/m2) groups (P ¼ .98) in
the older patient group. Using logistic regression modeling,
we estimated the probability of SVD among patients less
than 20 years of age at the time of PVR according to indexed
valve ID, which is shown as a logistic curve (Figure 3) and
is statistically significant (P< .001). In addition, logistic
regression confirmed that in patients older than 20 years
at the time of PVR, indexed valve ID was not predictive
(P ¼ .65) of SVD.
DISCUSSION
Patients experienced significant reductions in RVEDV,
RVEDVI, degree of PR and TR, PR fraction, peak PV gra-
dient, and estimated RV pressures after PVR. In our study
younger age at the time of PVRwas found to be a significant356 The Journal of Thoracic and Cardiovascular Surgpredictor of reduced time to SVD. Although amoderate cor-
relation was seen between valve size and age at the time of
PVR, valve size was not an independent predictor of SVD
when performing covariate analysis. However, higher in-
dexed valve ID at implantation, which is indicative of valve
oversizing, was an independent predictor of SVD within
younger patients. This suggests that valve oversizing in
younger patients might contribute to SVD. MRI and echo-
cardiographic measures studied were not predictors of
SVD. Valve type and manufacturer were not significant pre-
dictors of SVD at short-term follow-up.
Numerous studies have previously evaluated predictors
for valve deterioration after RVOT reconstruction in pa-
tients with congenital heart disease.14-20 These large
series have typically included multiple congenital heart
disease diagnoses within the study population and have
investigated all types of PVR options, including
bioprosthetic, homograft, and mechanical valves, with
few reviewing stented bioprosthetic valves alone. Despite
their variation, younger age at the time of PVR has
previously been reported as a risk factor for pulmonary
valve reintervention.14,20 Zubairi and colleagues20 reported
age less than 10 years to be a risk factor for repeat pulmo-
nary valve intervention. Caldarone et al14 further identified
age range specific risk factors for SVD after they stratified
their patient population by age. They identified an increased
risk for valve failure with an age at PVR less than their ref-
erence range of 15 to 18 years. In our study 93% of those
who underwent a reintervention were younger than 20 years
at the time of initial PVR, although our median age at the
time of PVR was 19.4 years.
There are several possible explanations for the relation-
ship between younger age and accelerated SVD. Somatic
outgrowth of a small conduit is generally considered the
most common mode of failure for homograft and xenograftery c February 2012
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Dconduits implanted into small children. In our cohort there
was a correlation between age and the size of the valve im-
planted, with younger patients receiving smaller valves.
However, valve size was not an independent predictor of
SVD when accounting for age at implantation. Moreover,
SVD in this series was almost exclusively caused by PR
rather than PS, suggesting mechanisms other than out-
growth. Interestingly, patients with SVD tended to receive
valves with a larger indexed valve ID than patients in the
non-SVD group. A significant correlation between higher
indexed valve ID and SVD suggests that oversizing of the
prosthesis might play a role in accelerated SVD. Even
though age, independent of indexed valve ID, was a predic-
tor of SVD, there was a very strong correlation between
young age and an oversized valve. Valve oversizing has
been associated with accelerated SVD in other types of con-
duits in the RVOT.21 Alterations in flow dynamics across an
oversized valve might be the mechanism underlying this
phenomenon. Patient-related factors, including immuno-
logic response and hemodynamic factors, might play
a role in accelerated valve deterioration as well. Lastly,
the bioprostheses studied have been designed for optimal
performance in the systemic circulation with higher pres-
sures than in the pulmonary circulation, and differences in
leaflet stress characteristics might affect durability.
The correlation of age with SVD might have important
implications. Despite younger age being a predictor of
SVD, prolonging PVR could expose patients to the delete-
rious effects of RV dilation. The balance between these
competing risks must also include the risk of reoperation
when SVD occurs, and this balance might also be affected
by the availability of transcatheter valve technology. The
optimal timing of PVR for pulmonary valvular insuffi-
ciency will depend on the interaction of these multiple
risk factors, which will, in turn, depend on the longer-
term outcomes after these various interventions.
Significant attention was paid to the correlation identified
between age and indexed valve ID. As expected, younger
patients were found to have significantly higher indexed
valve IDs. Thus, not surprisingly, the phenomenon of valve
oversizing was limited to younger children, given more ap-
propriate sizing in adult patients. This association in youn-
ger children was depicted in our logistic regression curve,
which highlights the increasing probability of SVD with in-
creasing indexed valve IDs. On the basis of these results, we
believe oversizing of valves should be limited during PVR
in young children.
Our definition of SVDwas in accordance with previously
published guidelines regarding reporting after cardiac valve
interventions.11 In contrast to some previous studies ad-
dressing long-term outcomes after PVR, this study included
patients with moderate PR or PS within our SVD group.
This was deemed appropriate because most patients who
required reintervention had at least moderate PR at theThe Journal of Thoracic and Catime of reintervention. The criteria were designed to cap-
ture patients who have experienced some level of valve
deterioration after PVR and are at risk for eventual
reintervention.
Similar to previous reports,7,22 this study also identified
significant reductions in MRI and echocardiographic
parameters postoperatively. A significant improvement in
TR was found in 30% of patients, presumably because of
RV remodeling and improved tricuspid leaflet coaptation.
Although a significant decrease in RVEF on postoperative
MRI at most recent follow-up was seen, this finding is likely
due to selection bias because patients with more severe
disease are followed more frequently with routine MRI,
as opposed to echocardiography alone.
This study is limited by the duration of follow-up,which is
associatedwith the relatively recent use of theCEMagna and
Sorin Mitroflow valves, which were US Food and Drug Ad-
ministration approved in late 2003 and 2007, respectively.
No statistically significant differencewas identified between
valve types as a predictor for SVD when accounting for du-
ration of follow-up. This finding highlights the need for con-
tinued long-term patient follow-up after PVR. In addition,
this study reports outcomes at a single institution and might
not necessarily be generalized to other institutions.
In conclusion, younger age at the time of PVR was found
to be a significant predictor of reduced time to SVD, and
oversizing of the implanted valve might predispose younger
patients to early SVD. These study results could potentially
affect the timing of PVR and the extent of valve oversizing
in small children. Further long-term follow-up needs to be
completed before conclusions can be generated regarding
the durability of the various types of stented pericardial
valves implanted in the pulmonary position. Additionally,
more data will need to be collected to identify the optimal
range for valve sizing during PVR in younger children.
PVR in this patient population does significantly improve
clinical radiographic parameters seen on echocardiographic
analysis and MRI.References
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Dr Carl L. Backer (Chicago, Ill). I want to congratulate Dr
Chen and his colleagues from Children’s Hospital of Boston on
their outstanding results with PVR in children and young adults
with repaired TOF. A total of 229 operations with no mortality
and no significant morbidity is truly a notable achievement.
I believe this review is timely for 2 reasons. One is our current
emphasis on pulmonary valve preservation during the initial TOF
repair. The fact that 229 patients were believed to need PVR after
TOF repair emphasizes the importance of pulmonary valve preser
vation, if possible, at the time of the initial operation.
The second reason this presentation is quite timely is the current
increase in the use of transcatheter pulmonary valve insertion for
appropriate patients. This leads me to my first of 3 questions.
It is my impression in our practice that the availability of trans
catheter pulmonary valve insertion has actually led to an increase
in the number of referrals for surgical PVR. The placement of a sur
gical valve gives the interventional cardiologist a future landing358 The Journal of Thoracic and Cardiovascular Surgsite for their transcatheter valve. This changes the treatment para
digm from valve deterioration, leading not to another operation but
to a transcatheter intervention. My first question then is this: Has
the introduction of the percutaneous pulmonary valve changed
your management paradigm for these patients?
Dr Chen. Thank you very much for the comments and the
question.
Regarding whether the criteria for pulmonary valve reinterven
tion differ with the advent of transcatheter valves, I do not believe
there is a difference. The same indications for valve reintervention,
namely symptomatic PR or an RVEDVI of greater than 150ml/m2,
apply for surgical PVR, as well as transcatheter valve replacement.
I would have to say that the criteria have definitely changed over
the duration of our study period toward earlier reintervention and
in patients with even mild RV dilation. However, these guidelines
again hold for both surgical and transcatheter valve replacement at
our institution.
Dr Backer. My second question is directly tied to the title of
your article, which was somewhat provocative. If younger age is
a predictor of SVD, are you now delaying some pulmonary valve
operations despite, for example, an RVEDV of 160 mL/m2? For
a patient like that who is, for example, 14 or 15 years old, would
you now wait until they are older to place the valve? In other
words, is this finding in your article a statistical anomaly, or is it
truly something that is going to have a clinical effect?
Dr Chen. I believe our findings could potentially have some
significant clinical effect in the future. However, despite the find
ings, currently, we would not necessarily endorse delaying surgi
cal intervention. At our institution, practices have not changed
despite our study results. Again, as you stated, the primary goal
is preservation of RV function. If the debate is between whether
you want to deal with earlier valve deterioration and an extra op
eration versus the complications that come with chronic pulmo
nary insufficiency and RV dilatation, specifically arrhythmias
and sudden death, I think the majority would not delay surgical in
tervention. Therefore because of the potential complications asso
ciated with delaying reintervention, our practices have not
changed.
On the basis of our results, we do believe that attention should
be placed on developing a systematic approach to defining the op
timal timing of reintervention and weighing the advantages and
disadvantages of delaying surgical intervention. In addition, we
believe greater attention should be paid to avoiding oversizing,
which was a newer finding in our study. In particular, we will
plan to look more closely at the possibility that valve oversizing
in relation to body surface area might be contributing to the earlier
valve failure seen in our reintervention group.
Dr Backer. My final question relates to the technical details of
this operation. Some surgeons routinely do this with aortic cross
clamping, and some do this with a beating heart. For many years,
our standard approach has been to use a crossclamp for these pa
tients. We only use a beating heart strategy in a very complicated
reoperation with difficult dissection after a careful bubble study
with Valsalva at the beginning of the case with transesophageal
echocardiographic analysis showing no evidence of any intracar
diac shunts. Reading your article, you had no neurologic compli
cations in this series. Whatever your surgical strategy was, it
was quite a good one, and perhaps you would like to share withery c February 2012
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Dus your guideline regarding the indications for crossclamp versus
beating heart surgery for pulmonary valve insertion.
Again, I congratulate you on your outstanding results and excel
lent presentation.
Dr Chen. The practices differ between the surgeons; however,
typically, if there is any residual shunt, these are captured on
a preoperative catheterization in which the cardiologist specifi
cally probes for a patent foramen ovale or during an intraoperative
transesophageal echocardiogram with a bubble study, as you men
tioned. In these cases in which a residual shunt is identified, cross
clamping would be used.
In addition, crossclamping can be used for better exposure. Oth
erwise, we do not necessarily use crossclamping in all patients un
dergoing a PVR.
Dr J. William Gaynor (Philadelphia, Pa). I would like to ask
one question about the mechanisms of the valve failure. The youn
ger age would suggest that perhaps this is an accelerated calcifica
tion of the leaflets with degeneration. The oversizing would
suggest that perhaps there is distortion of the struts. Do you have
any data on the mechanisms of a failure when they differ for those
that fail in the younger patients versus those with the oversized
valves?
Dr Chen. Aside from whether the primary mode of valve fail
ure was PR or PS, we do not have any additional data. As I men
tioned, the majority of the patients had echocardiographic or MRI
evidence of PR before reintervention. Some patient had a combina
tion of both regurgitation and stenosis.
Dr Gaynor. Was there leaflet deterioration or distortion of the
struts in any of the valves before explantation?
DrChen. Unfortunately, we do not have that information today;
however, looking more specifically at individual operative notes
would be very useful in determining this.
Dr Richard A. Jonas (Washington, DC). I rise to reinforce the
point that Carl Backer was just making about the risks of neuro
logic injury. I am sure some of the people in this room have
been asked to review cases of severe brain injury or death that
have occurred in the not too distant past as we do more and
more of these PVRs. It is for sure an important risk if the operation
is done with a beating heart.
The problem is often entrainment of air. For example, if you cut
into the original outflow patch as you are reopening the sternum
and you get frothing in the right heart from the heart action, then
that froth can be drawn through the foramen ovale with the heart
continuing to beat. Or if you are using a single venous cannula
or 2 stage cannula and you are entraining air through the tricuspid
valve and the heart is continuing to beat, you can definitely get
enough air into the left side to cause severe brain injury.
Therefore another option, if you are not confident, as I am not,
that a transesophageal echocardiogram is always going to show
you a right to left shunt at the atrial level through a foramen ovale,
is to use electrical fibrillation. We find that that this is the best way
to do this operation. You do not have to dissect out the aorta. In
fact, I am using more and more electrical fibrillation. You can
do it at relatively mild hypothermia. Therefore this is my question
for you: Are you using ventricular fibrillation?
Dr Chen. Unfortunately, I might have to defer this question to
Dr Pigula, who is here representing the group. I cannot comment
on that.The Journal of Thoracic and CaDr Frank Pigula (Boston, Mass). I agree completely with ev
erything you said, and we do use electrical fibrillation. We have
a very low threshold for either crossclamping or using electrical fi
brillation if there is any question regarding the status of the atrial
septum. Because the transesophageal echocardiogram is not 100%
sensitive, I am not willing to bet somebody’s life on it.
I just want to take this moment to make a couple of other com
ments regarding the mode of failure of these valves. I think it is im
portant because of the introduction of the percutaneous valve.
There might be implications for how the current generation of sur
gically implanted valve fails and how suitable it will be for a trans
catheter valve in the future. In other words, if it were a stenotic
failure or a collapse of the struts, that might have a different impli
cation on a transcatheter valve than a valve failing because of re
gurgitation. Also, we have not really seen valves that have failed
from strut collapse or stenosis in these patients.
Over time, our indications have changed. The cardiologists and
we do use the same indications for valve placement, and that is
usually at an end diastolic volume of about 150 mL/m2.
However, I do think that our criteria for PVR has changed, and
the availability of a percutaneous valve might have influenced that.
DrAliMumtaz (Norfolk, Va). My question is very brief regard
ing theMitroflow valve. I noticed you have a very large experience
with that. There was one slide that showed that something was sta
tistically significant in this group of patients. Just out of curiosity,
of the 58 valves you used, how many of them failed in that 1 year
follow up?
Dr Chen. There were a total of 4 patients within the Sorin Mi
troflow group who fit our criteria for SVD. There were no reinter
ventions in this group.
Dr Mumtaz. That is a significant failure for just 1 year. I have
found the same thing in the CE bovine pericardial valve; there is an
incidence of early failure in the pulmonary position. That is why I
was curious to ask if that is any different.
DrChen. Therewere 4 patients of our 58 in the SorinMitroflow
group who had the criteria of valve deterioration, none of whom
required reintervention. However, it would be very interesting to
look at each patient and identify a specific mode of early valve
failure.
Dr Jonathan Chen (New York, NY). This might be a question
for Frank, too, given that the primary mode of failure was
regurgitation, and given that we are assuming that this valve
inside of a valve percutaneous strategy will work in the future. I
used to always try to oversize these pulmonary prostheses as big
as we could, thinking that the mode of failure was going to be
a combination of stenosis and regurgitation and that the actual in
ternal orifice was going to get smaller and smaller, and therefore
they ultimately were going to be able to put a Melody valve inside.
For example, if you put a 29 mm valve in the orthotopic position,
then perhaps it could one day provide the support structure for
a 25 mm Melody valve.
But now I am told by our interventionalists that the SAPIEN
valve is the only one that is as big as 27mm. Therefore the question
is this: If it is mostly regurgitation and not stenosis, should we be
putting in any valves that are over size 27 mm?
Dr Pigula. I will answer that one. I think that one of the take
home messages I have from this is that oversizing the valve is
not necessarily an advantage. For most patients, a 25 mm valverdiovascular Surgery c Volume 143, Number 2 359
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Dis large enough and provides a suitable landing zone for the current
generation of percutaneous valves.
The other information, and I think Bill brought it up, is whether
it is calciummetabolism that is leading to the valve deterioration in
younger patients or whether it is the fact that those valves are over-
sized for younger and smaller patients. Therefore I have gone to
just sizing a 25-mm valve unless there is an obvious reason to
use something larger.
Dr Frank L. Hanley (Stanford, Calif). I just had a few more
thoughts about the beating heart and the potential for neurologic
injury. It is clearly an extremely important point because it can
be devastating.
We did a little study many, many years ago in which we did bub-
ble studies on the right side and then obligatorily had to open the
heart in a certain percentage of those patients, and we checked spe-
cifically for patent foramen ovale. Of all of the patients who had
a negative bubble study result, I think we found patent foramen
ovale in 25% or 30%. Therefore it is clearly not a complete
safeguard.360 The Journal of Thoracic and Cardiovascular SurgHowever, we routinely do all of these cases on a warm beating
heart. What we do is the bubble study; we do a left-sided and
right-sided bubble study. Even then, if the results of both of those
are negative, wewill proceed with a warm beating-heart procedure.
However, I specifically look the anesthesia fellow in the eye-and I
guess you have to have the luxuryof having at least 2 anesthesia peo-
ple-but I look the anesthesia fellow in the eye and say, ‘‘As long as
this right ventricle is open, don’t take your eyes off that echo ma-
chine.’’ At even the first bubble that goes across, we will then abort
and do something else. Most of the time, you are fine; occasionally,
you will see 1 or 2 bubbles come across, and then you can make
a change. But if you do that, you have a very, very complete safe-
guard, and you can domost of these on awarmbeating heart, I think.
Dr Pigula. The only thing I wanted to add to Dr Hanley’s com-
ments is that the other thing I will ask the anesthesiologist to do is
make sure the perfusion pressure stays up to keep the aortic valve
closed during the case. Therefore I will always ask them to leave it
at maybe an extra 10 mmHg higher to give me a little extra margin
of safety and to prevent the ventricle for injecting.ery c February 2012
